Veeda Clinica Research
-3.03 % 1 MAbout Veeda Clinica Research
A Comprehensive Overview of Price & Journey
Understanding Veeda Clinica Research Inception and Growth
Veeda Clinical Research Share Price Details
Particular
Details
Company name
Veeda Clinical Research Limited
Industry
Clinical research and healthcare
Incorporated
2004
ISIN
INE01HQ01026
Face value
₹2 per share
Share status
Unlisted
DRHP status
Reported as filed
IPO date
No confirmed date stated here
The quoted price is indicative rather than a guaranteed execution price. Confirm the current quote, minimum lot size, applicable charges and share-transfer process directly with a verified intermediary before making a transaction.
Company Overview
Veeda Clinical Research Limited is an Indian contract research organisation (CRO) that provides research services to pharmaceutical and biotechnology companies. Its work supports the process of evaluating drug safety, effectiveness and performance during different stages of development.
The company was established in 2004 and is headquartered in Ahmedabad, Gujarat. Its services include clinical research, bioequivalence studies, early-phase research, later-stage clinical trials and pharmacovigilance.
Clinical research organisations play an important role in drug development by helping sponsors conduct studies, collect reliable data and meet applicable regulatory requirements.
Business Activities of Veeda Clinical Research
Veeda's business is based on providing research and development support to pharmaceutical and healthcare companies. Its main service areas include:
-
Clinical trials: Supporting studies that evaluate medicines and treatments in human participants.
-
Bioequivalence studies: Assessing whether different drug formulations demonstrate comparable performance under specified conditions.
-
Early-phase research: Supporting initial clinical evaluation of investigational medicines.
-
Late-phase clinical research: Providing support for more advanced clinical studies.
-
Pharmacovigilance: Supporting the monitoring and assessment of medicine safety information.
Revenue from these activities can depend on the number and size of research projects, client demand, project timelines and the company's ability to manage operating costs.
SHOW MORE...
Veeda Clinical Research Share Price Details
| Particular | Details |
|---|---|
| Company name | Veeda Clinical Research Limited |
| Industry | Clinical research and healthcare |
| Incorporated | 2004 |
| ISIN | INE01HQ01026 |
| Face value | ₹2 per share |
| Share status | Unlisted |
| DRHP status | Reported as filed |
| IPO date | No confirmed date stated here |
The quoted price is indicative rather than a guaranteed execution price. Confirm the current quote, minimum lot size, applicable charges and share-transfer process directly with a verified intermediary before making a transaction.
Company Overview
Veeda Clinical Research Limited is an Indian contract research organisation (CRO) that provides research services to pharmaceutical and biotechnology companies. Its work supports the process of evaluating drug safety, effectiveness and performance during different stages of development.
The company was established in 2004 and is headquartered in Ahmedabad, Gujarat. Its services include clinical research, bioequivalence studies, early-phase research, later-stage clinical trials and pharmacovigilance.
Clinical research organisations play an important role in drug development by helping sponsors conduct studies, collect reliable data and meet applicable regulatory requirements.
Business Activities of Veeda Clinical Research
Veeda's business is based on providing research and development support to pharmaceutical and healthcare companies. Its main service areas include:
-
Clinical trials: Supporting studies that evaluate medicines and treatments in human participants.
-
Bioequivalence studies: Assessing whether different drug formulations demonstrate comparable performance under specified conditions.
-
Early-phase research: Supporting initial clinical evaluation of investigational medicines.
-
Late-phase clinical research: Providing support for more advanced clinical studies.
-
Pharmacovigilance: Supporting the monitoring and assessment of medicine safety information.
Revenue from these activities can depend on the number and size of research projects, client demand, project timelines and the company's ability to manage operating costs.
About Veeda Clinica Research
IPO Details, Price movement
Veeda Clinical Research Financial Performance
The available market-data sources report the following financial figures.
FY 2024–25 Standalone Results
| Financial indicator | Reported amount |
|---|---|
| Revenue | ₹610 crore |
| EBITDA | ₹125 crore |
| Profit after tax | -₹67 crore |
| EBITDA margin | Approximately 20.5% |
These figures are reported on a standalone basis by UnlistedHub. Standalone figures should not be confused with consolidated results, which include subsidiaries where applicable.
FY 2025–26 Consolidated Results
| Financial indicator | Reported amount |
|---|---|
| Revenue | ₹715.5 crore |
| EBITDA | Approximately ₹209.4 crore |
| Profit after tax | -₹14 crore |
| Net worth | ₹1,120.4 crore |
| Borrowings | ₹421.4 crore |
These figures are reported by UnlistedHub from its financial-data review. Investors should verify them against the company's audited financial statements before relying on them.
The reported consolidated revenue increased year on year, while the company continued to report a net loss for FY 2025–26. This makes it important to evaluate profitability, cash flow, financing costs and future earnings rather than relying on revenue growth alone.
Fundamentals
Financials
All values are INR Cr except per share value
| P&L Statement | 2023 | 2024 |
|---|---|---|
| Revenue | 223.93 | 296.15 |
| Other Income | 4.23 | 9.15 |
| COGS | 18.83 | 17.81 |
| Gross Profit | 209.33 | 287.49 |
| Total Expense | 164.02 | 223.93 |
| EBIDTA | 45.31 | 63.56 |
| D&A | 15.53 | 21.13 |
| EBIT | 29.78 | 42.43 |
| Interest Expense | 4.58 | 5.33 |
| PBT | 25.20 | 37.10 |
| TAX | 6.87 | 11.15 |
| PAT | 18.33 | 25.95 |
| Diluted EPS | 3.90 | 4.90 |
| Basic EPS | 3.91 | 4.91 |
| Total income | 228.16 | 305.30 |
ASSETS
| CURRENT ASSETS | 2023 | 2024 |
|---|---|---|
| Cash and Cash Equivalents | 57.72 | 33.32 |
| Trade Payables | 77.39 | 71.14 |
| Inventory | 6.99 | 4.90 |
| Other Current Assets | 163.03 | 153.47 |
| Total Current Assets | 305.13 | 262.83 |
| NON CURRENT ASSETS | 2023 | 2024 |
|---|---|---|
| Plant Property and Equipment | 77.71 | 107.17 |
| Long Term Investment | 165.13 | 213.15 |
| Other Non Current Assets | 48.67 | 77.34 |
| Total Non Current Assets | 291.51 | 397.66 |
| Total Assets | 596.64 | 660.49 |
|---|
| CURRENT LIABILITES | 2023 | 2024 |
|---|---|---|
| TRADW Payable | 21.48 | 19.19 |
| Other Current Liab | 67.20 | 77.21 |
| NON CURRENTLIABILITIES | 2023 | 2024 |
|---|---|---|
| Other Non Current Liab | 34.24 | 42.88 |
LIABILITIES
| EQUITY | 2023 | 2024 |
|---|---|---|
| Share Capital | 10.57 | 10.58 |
| Other Equity | 463.18 | 510.60 |
| Total Equity | 473.75 | 521.18 |
| Total Liabilities & Equity | 473.75 | 521.18 |
|---|
| CASH FLOW STAT | 2023 | 2024 | ||
|---|---|---|---|---|
| Cash Flow from operating | - | - | 12.73 | 75.06 |
| Cash Flow from financing | - | - | 172.10 | 8.15 |
| Cash Flow from investing | - | - | -141.83 | -106.71 |
| Net cash flow | 0.00 | 0.00 | 43.00 | -23.50 |
Revenue Growth
PAT Growth %
EPS Growth %
TOTAL ASSETS Growth %
QUICK RATIO Growth %
LONG TERM DEBT TO EQUITY RATIO Growth %
Shareholding Pattern
2026
| Name | Designation | Share % |
|---|---|---|
| Basil Private Limited | NA | 35.52% |
| Bondway Investment Inc | NA | 20.45% |
| Sabre Partners AIF Trust | NA | 4.38% |
| Others | NA | 39.65% |
Events
| Name | Date | Details |
|---|---|---|
| No events available. | ||
Frequently Asked Questions
Like any other financial product or commodity, the price of unlisted shares is discovered at the intersection of demand from buyers and supply from sellers of particular unlisted shares.
The two determinants of price are dynamic factors and keep changing constantly, hence share price tends to fluctuate constantly – every day, every minute.
Upon successful completion of a deal, the unlisted shares are credited electronically directly to your standard demat account that is usually created with CDSL or NSDL (Central Depository Services Limited or National Securities Depository Limited).
The lock-in period of Veeda Clinica Research varies depending on the category of the investor:
-
Venture capital or foreign venture capital investors are subject to lock-in period of 6 months from the date of acquisition of shares
-
For AIF investors of Category-II are not subject to any lock-in.
-
Any other investor, including retail investors, HNI or corporate investors are subject to a lock-in period of 6 months from the date of listing.
Note – The above-mentioned lock-in is for mainboard, however for SME IPO the applicable lock-in period is 1 Year.
There is no regulatory minimum limit to invest in unlisted shares. However, minimum investment size varies with the per share price. Earlier, the typical investment size often ranges between 70K – 100K, but with the growing awareness and increased participation the investment size has been down sized to 50k.
Short-Term Capital Gain tax is applicable when you sell your unlisted shares within a year from date of acquisition. Realized gain is taxable at your slab rate after consolidating in total income for the year. Hence, the rate of tax depends on your overall income for the particular financial year.
Long-Term Capital Gain taxes are applicable when you sell your unlisted shares after two years from the date of acquisition. LTCG tax is calculated on profits realized on sale of unlisted shares at 12.5%. Investors particularly retail or HNI must understand the concept clearly as it impacts strategy and tax planning.
-
You can download the NSDL or CDSL application and login into the account and check whether the shares have been credited or not.
-
Credit of Unlisted Shares/Pre-IPO shares can be checked in brokers application as well but it takes T+2 days to show the shares.
-
You would also get email confirmation of credit of shares via email
-
The value of share in unlisted space is determined in the same way as it is done in the listed market. Demand and supply decide the price of any share. If the demand is more than the supply, then the price of the share increases and vice versa.
-
When a new share is introduced in the unlisted space, the value of the company is decided upon the last funding raised by the company. If the company hasn’t raised any funding in the past, then the valuation is decided upon the fundamentals of the company.
Yes, investing in unlisted shares is legal in India, the activity is regulated and governed under the rules and guidelines laid by SEBI (Securities and Exchange Board of India). Related parties must comply with the regulations and guidelines to ensure legal and financial standards.
Investing in unlisted shares in India carries a significant and distinctive risk profile such as limited liquidity, lack of transparent pricing and regulatory oversight because unlisted shares do not trade on listed stock exchange, they are bought or sold in OTC (over the counter) market that makes vulnerable to following risks:
-
Liquidity risk, unlisted shares are difficult to buy and sell,
-
Lack of transparent pricing, as share price of pre-IPO or unl;isted company is often determined by narrative not fundamentals
-
Lack of information disclosure, unlisted companies are not mandated for disclosures like listed companies
-
Tax ambiguity, because determination of fair market value and cost of acquisition of unlisted shares is often disputed
Hence, investors should carefully examine related facts before investing in Pre-IPO or unlisted shares.